Skip to main content

Table 4 Least squares MADRS score change (mean, SE) during treatment in bipolar I and II subgroups (ITT population)

From: Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression

Treatment Bipolar I
n = 1162
Bipolar II
n = 598
n Least squares MADRS score change (mean, SE) Probabilitya n Least squares MADRS score change (mean, SE) Probabilitya
Quetiapine
 Week 4 944 −15.01 (0.27) <.01 484 −13.96 (0.38) <.01
 Week 8 781 −19.01 (0.30) <.01 422 −18.44 (0.41) <.01
Lithium   N = 87    N = 49  
 Week 4 74 −11.16 (0.98) NS 41 −10.46 (1.31) NS
 Week 8 66 −17.71 (1.03) <.05 34 −17.46 (1.43) NS
Paroxetine   n = 74    n = 44  
 Week 4 59 −12.01 (1.09) NS 38 −13.38 (1.36) NS
 Week 8 45 −16.54 (1.24) NS 31 −15.35 (1.50) NS
Placebo   n = 486    n = 231  
 Week 4 388 −11.31 (0.43) 198 −10.17 (0.60)
 Week 8 304 −14.29 (0.48) 164 −14.57 (0.65)
  1. Analyses conducted using a linear mixed model (MMRM)
  2. ITT intent-to-treat, MADRS Montgomery–Åsberg depression rating scale, NS nonsignificant
  3. aProbability of comparison in change from baseline between treatment and placebo